SAN DIEGO, CA -- November 19, 2002 -- TargeGen, Inc. a biotechnology company focusing on ischemic diseases and cancer, today announced the appointment of David F. Ranney M.D., to its Scientific Advisory Board.

Dr. Ranney currently serves as Managing Director of Global BioMedical Solutions (Dallas, TX), a drug development consulting group. Previously, he was a co-founder of Hybrigen, a functional proteomics company, and the founder of Access Pharmaceuticals, a drug delivery and speciality pharmaceutical company, where he also served as Chairman and headed the company's R&D programs. He has also served as an Assistant Professor of Radiology and Pathology and an Adjunct Professor of Radiology at the University of Texas Southwestern Medical Center. Dr. Ranney is an inventor or co-inventor on 11 issued patents in the fields of drug delivery, particle technologies and imaging agents. After receiving his B.A. at Oberlin College, Dr. Ranney earned an M.D. with Alpha Omega Alpha honors from Case-Western Reserve Medical School (Cleveland, OH).

"We are extremely pleased to have someone of Dr. Ranney's experience and stature in the fields of drug development, formulations and particle-based technologies join our Scientific Advisory Board," said Peter G. Ulrich, President and CEO of TargeGen. "TargeGen will certainly benefit from his distinguished years of achievement as we advance our ischemic disease and cancer programs into human clinical trials and seek to build a top tier pharmaceutical company".

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company established in July 2001. TargeGen is developing novel therapeutics to treat cancer and ischemic disease (stroke, heart attack) by regulating the processes associated with new blood vessel formation (angiogenesis) and vascular permeability (VP).

In March 2002, TargeGen executed a comprehensive licensing agreement with Merck KGaA (Darmstadt, Germany). This agreement provided TargeGen with access to a portfolio comprised of more than 100 pending and issued patents in the field of vascular biology. Also in March 2002, TargeGen completed a $10M Series "A" financing. The company's first funding round was led by Forward Ventures (San Diego), with significant participation by Enterprise Partners (La Jolla) and other investors.

For additional information, contact:
Peter G. Ulrich, President & CEO
TargeGen, Inc.
9393 Towne Centre Drive
Suite 120
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
ulrich@targegen.com
http://www.targegen.com